array (CBA) immunoassay [4] using a BD Biosciences LSR Fortessa X-20™ cell analyser (Becton Dickinson, Oxford, UK) using stored sera from 52 subjects. A one-time cross-sectional measurement was performed-intra-individual variability was not assessed.
Results were compared with inflammatory disease control groups of 10 Sjögren's syndrome patients with high fatigue (Visual Analogue Scale to Evaluate Fatigue VAS-F >75) and 10 with low fatigue (VAS-F <25) and 15 healthy controls, matched for sex and age. XL-CGD carriers were divided into two groups: those who reported fatigue and those who did not. Median age of XL-CGD carriers was 41.5 years (range 8.5-65.9), 96% Caucasian British. Median age of healthy controls was 46.0 (range 25-60) and median age of Sjogren's syndrome controls was 48.5 (range 25-64). Statistical analysis was undertaken between the groups using STATA, and medians were compared using a Mann-Whitney U test for non-parametric data. A p value ≤0.05 was considered statistically significant.
Forty-eight percent (25/52) of XL-CGD carriers reported suffering excessive fatigue, associated with significantly higher scores in the MFSISF (p < 0.01). There were no differences between those with relatives with CGD who had or had not been transplanted, thus controlling for fatigue associated with the psychological stress of caring for a dependent with a serious disease.
Interleukin (IL)-8 levels were significantly higher in XL-CGD carriers (median 122u/ml) than in healthy controls (median 28u/ml) (p = 0.015) and all patients with Sjögren's syndrome (median 17u/ml) (p = 0.031) (Fig. 1) . IL-8 levels were also significantly higher in the group of XL-CGD carriers who reported high levels of fatigue (median 235u/ml) than in those not reporting fatigue (median 31u/ml) (p = 0.017).
There were no significant differences in IL-8 between high and low fatigue Sjögren's syndrome groups (p = 0.45). No other cytokines reached statistically significant different levels between groups. Many XL-CGD carriers reported high levels of fatigue. The significantly higher serum IL-8 levels in XL-CGD carriers than healthy and Sjögren's syndrome controls and the significantly higher levels in those reporting fatigue may suggest a biological explanation for the symptoms. Previous studies have associated raised IL-8 with excessive fatigue [5] , but this is the first study to evaluate fatigue and pro-inflammatory cytokines in XL-CGD carriers. However, there was no correlation between the fluorescent intensity on the dihydrorhodamine test and serum concentration of IL-8 (Pearson correlation coefficient 0.086, p = 0.551).
Potential confounders were investigated. There were no differences in fatigue within families who had transplanted or non-transplanted index cases. Age was not correlated with IL-8 (Pearson correlation coefficient −0.10, p = 0.358). Unpaired T test showed no significant differences in age between fatigued and non-fatigued individuals in the XL-CGD group (p = 0.144) and in all samples (p = 0.560). Although the serum samples were obtained at different time periods, they were collected at the same time as data about fatigue levels and there were no seasonal variations in IL-8 level (KruskalWallis for non-parametric data p = 0.777). No information on infectious, inflammatory, or autoimmune symptoms was gathered systematically during this study.
Despite the limitations of the study, in particular that this was a one-time cross-sectional measurement with no intra-individual variability assessment, we believe that this is an important finding and demonstrates for the first time that many XL-CGD carriers, previously thought to be unaffected, experience significant fatigue for which there may be a biological cause. Previous studies have shown that gene expression of pro-inflammatory cytokines is upregulated in neutrophils from XL-CGD patients, including IL-8 [6] . While similar observations have not been demonstrated in XL-CGD carriers, it is likely that the phagocyte population expressing the mutated X-chromosome would show similar findings. Further research is required to evaluate this finding in XL-CGD carriers. Importantly, the finding of a potential biological explanation for the symptoms of fatigue opens the possibility of therapeutic intervention for this population.
